Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of NIM811 plus standard of care in chronic hepatitis C genotype 1 relapsers
2009-009995-11Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2009
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of NIM811 in hepatitis C virus infection, sponsored by Novartis. Primary endpoints: Safety and tolerability at 4 weeks and Rapid virologic response (RVR). Started Apr 2009; status: completed.
02
Drugs
NIM811
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-009995-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009995-11.